PharmaCyte Biotech, Inc.'s plan to develop new treatments for insulin-dependent diabetes was one of the focuses of the second annual meeting of the company's International Diabetes Consortium in Vienna, Austria.
PharmaCyte develops targeted treatments for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box.
“The data presented at the meeting of the International Diabetes Consortium clearly show that PharmaCyte is making excellent progress in developing what we believe will become a new game-changing therapy for insulin-dependent diabetes - a debilitating and even life-threatening disease with an ever increasing incidence that affects so many around the world," PharmaCyte CEO Kenneth Waggoner said.
During the meeting, results from safety tests on PharmaCyte's other signature therapy, Melligen cells, was presented along with data on the expansion of the parameters of encapsulated cells and preliminary studies in animal models.
PharmaCyte discusses signature therapies at International Diabetes Consortium